As we know Biotech can be a bit of a rollercoaster, so worthwhile starting a dialogue on 'biotech valuations'. Has the market been looking at this wrong the whole time. What approaches might be viable to ensure that biotech innovation prevails, whilst continuing to be a sustainable investment.
Part 1, more to follow:
DYOR - Opinion only not advice and not to be relied on.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.025(1.58%) |
Mkt cap ! $279.7M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.70 | $1.58 | $265.3K | 161.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1843 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2025 (20 minute delay) ? |
| RAC (ASX) Chart |